Akcea Therapeutics, Inc. (AKCA) held by 0 SEC 13F Filers

Akcea Therapeutics, Inc. (NASDAQ:AKCA) recovered 105.06% of its value since hitting low of $8.10. The recent move of -6.42% drop pushed the stock to close at $16.61 when trading ended on 11/06/2017. At recent session, the prices were hovering between $16.31 and $18.05. This company shares are 42.5% off its target price of $23.67 and the current market capitalization stands at $1.06B. The recent change has given its price a -26.64% deficit over SMA 50 and -46.81% deficit over its 52-week high. The stock witnessed -40.59% declines, 12.99% gains and 0% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AKCA’s volatility during a week at 7.83% and during a month it has been found around 8.81%.

Akcea Therapeutics, Inc. (AKCA) Top Holders

Institutional investors currently hold around $4 million or 12.6% in AKCA stock. Look at its top three institutional owners. Candriam Luxembourg S.C.A. owns $3.41 million in Akcea Therapeutics, Inc., which represents roughly 0.32% of the company’s market cap and approximately 85.23% of the institutional ownership. Similar statistics are true for the second largest owner, Nationwide Fund Advisors, which owns 7,552 shares of the stock are valued at $134 thousand. The third largest holder is Strs Ohio, which currently holds $76 thousand worth of this stock and that ownership represents nearly 0.01% of its market capitalization.

Akcea Therapeutics, Inc. 13F Filings

At the end of 09/30/2017 reporting period, 6 institutional holders increased their position in Akcea Therapeutics, Inc. (NASDAQ:AKCA) by some 204,904 shares. That puts total institutional holdings at 204,904 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 204,904 shares w.

Akcea Therapeutics, Inc. (AKCA) Analyst Guide

Several analysts have released their opinion on Akcea Therapeutics, Inc. (NASDAQ:AKCA), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.

Previous articleHouston American Energy Corp. (HUSA) added to 1 new portfolios
Next articleWhich insiders are buying Anavex Life Sciences Corp. (AVXL)?